News
BIIB
253.40
+0.06%
0.15
Will New Trial Data Change Biogen (BIIB) Stock Narrative
Simply Wall St · 1h ago
Piper Sandler Reiterates Overweight on Biogen, Raises Price Target to $305
Benzinga · 2d ago
Why Biogen Rose Even Though It Swung To A Loss
Simply Wall St · 2d ago
Biogen And UCB Report Post-Hoc Phase 3 Data For DPZ Indicating Lower Disease Activity In Lupus
NASDAQ · 2d ago
Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), Biogen (BIIB) and Mettler-Toledo (MTD)
TipRanks · 3d ago
Biogen price target raised to $305 from $245 at Piper Sandler
TipRanks · 3d ago
Weekly Report: what happened at BIIB last week (1102-1106)?
Weekly Report · 3d ago
Biogen Reports Stronger SLE Responses With Investigational Dapirolizumab
TipRanks · 3d ago
UCB And Biogen Report Dapirolizumab Pegol Plus SOC Associated With Higher Response Versus Placebo On Novel TRM-SLE And Greater Sustained Low Disease Activity In Post-Hoc Phase 3 PHOENYCS GO Analyses
Benzinga · 3d ago
Biogen (BIIB) Alzheimer’s Updates Put Fair Value Questions Back In Focus
Simply Wall St · 4d ago
Kenvue Now #267 Largest Company, Surpassing Biogen
NASDAQ · 5d ago
Biogen Canada Announces Broad Private Drug Plan Coverage For ZURZUVAE, Expanding Access For Eligible Patients With Postpartum Depression In Adults Following Childbirth
Benzinga · 6d ago
Alzheimer’s Data Update Could Be A Key Test For Biogen Stock (BIIB)
Simply Wall St · 11/05 12:35
BeOne gains FDA priority review for Brukinsa label expansion
Seeking Alpha · 11/04 15:07
Nasdaq Next 100 teeters on key support as tech risk appetite tested
Seeking Alpha · 11/03 19:57
Analysts Offer Insights on Healthcare Companies: BrightSpring Health Services, Inc. (BTSG), Biogen (BIIB) and BioNTech SE (BNTX)
TipRanks · 11/02 16:26
Biogen Is Maintained at Buy by Guggenheim
Dow Jones · 11/02 14:39
Guggenheim Maintains Buy on Biogen, Raises Price Target to $300
Benzinga · 11/02 14:29
Biogen Buy Thesis Strengthened as TOPAZ Lupus Trial Outlook Drives Price Target Raise to $270
TipRanks · 11/02 14:17
Regeneron Pharmaceuticals To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Monday
Benzinga · 11/02 13:26
More
Webull provides a variety of real-time BIIB stock news. You can receive the latest news about Biogen Inc through multiple platforms. This information may help you make smarter investment decisions.
About BIIB
Biogen Inc. is a biotechnology company. The Company is focused on discovering, developing and delivering therapies. It has a portfolio of medicines to treat Multiple Sclerosis (MS), has introduced an approved treatment for Spinal Muscular Atrophy (SMA), co-developed treatments to address a defining pathology of Alzheimer's disease and launched an approved treatment to target a genetic cause of Amyotrophic Lateral Sclerosis (ALS). It markets a drug approved in United States, European Union and certain international markets for the treatment of Friedreich Ataxia (FA) in adults and adolescents aged 16 years and older. It is focused on advancing its pipeline in neurology, specialized immunology and rare diseases. Its marketed products include VUMERITY, TYSABRI, TECFIDERA, AVONEX and PLEGRIDY for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of FA, and QALSODY for the treatment of ALS. Its commercialized products also include EMPAVELI and SYFOVRE.